Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
-Parse Biosciences, a leading provider of cost-effective and scalable solutions for single-cell sequencing, today announced an agreement with the Taiwane...
Fifty 1 Labs, Inc. , a holding company that operates in the sports supplement, fitness equipment, and health and wellness industries, and All-In-Extracts...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with met...
Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has receive...
Takeda announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cy...
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI He...
InnoCare Pharma, a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...
Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation...
KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a le...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by...
Hyundai Bioscience announced its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cance...
© 2025 Biopharma Boardroom. All Rights Reserved.
